30 results about "Leucine+Isoleucine" patented technology

A microorganism is provided which has an ability to produce an L-amino acid such as L-lysine, L-tryptophan, L-phenylalanine, L-valine, L-leucine, L-isoleucine and L-serine, and has been modified to increase the activity of pyruvate synthase or pyruvate:NADP+ oxidoreductase. This microorganism is cultured in a medium containing ethanol or an aliphatic acid as the carbon source to produce and accumulate the L-amino acid in the medium or cells, and the L-amino acid is collected from the medium or the cells.

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ω-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

A microorganism is provided which has an ability to produce an L-amino acid such as L-lysine, L-tryptophan, L-phenylalanine, L-valine, L-leucine, L-isoleucine and L-serine, and has been modified to increase the activity of pyruvate synthase or pyruvate:NADP+ oxidoreductase. This microorganism is cultured in a medium containing ethanol or an aliphatic acid as the carbon source to produce and accumulate the L-amino acid in the medium or cells, and the L-amino acid is collected from the medium or the cells.

The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val (SEQ ID NO: 5), Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 9), and X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4 (SEQ ID NO: 10). The amino acids X1, X2, X3, and X4 can be each independently valine, leucine, isoleucine, or alanine; X5 can be glycine, alanine, leucine, isoleucine, or valine; X6, X7, X8, and X9 can be each independently glutamic acid or asparagine; X10 can be lysine or arginine; X11 can be methionine or cysteine; and X12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).

The invention discloses an alcohol dehydrogenase mutant and a use thereof. The alcohol dehydrogenase mutant is shown in the formula (1) and / or (2). (1) Phenylalanine at 147th of an amino acid sequenceshown in the formula of SEQ ID NO.1 is replaced by leucine, isoleucine, methionine or cysteine. (2) Alanine at 202th of the amino acid sequence shown in the formula of SEQ ID NO.1 is replaced with leucine, isoleucine or valine. A semi-rational design is used to modify the alcohol dehydrogenase LkADH derived from Lactobacillus kefir so that a plurality of alcohol dehydrogenase mutants are obtained. The alcohol dehydrogenase mutant has the characteristics of high enzyme activity, can efficiently catalyze t-butyl 6-chloro-3, 5-dicarbonylcaproate to prepare t-butyl (S)-6-chloro-5-hydroxy-3-carbonylcaproate and has a great significance for the production of statin drug intermediates.

Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.

The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided. The compound of formula (I) has the structure shown below, where -R6 and -R7 are each together with the carbonyl group and nitrogen alpha to the carbon to which it is attached an amino acid residue, except that R6 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a phenylalanine, leucine or valine residue and / or -R7 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a leucine, iso-leucine, phenylalanine, threonine, valine or nor-valine residue, and -T, -A1, -A2, -A3 and -R10 are as discussed in the application:

The invention discloses a method for preparing calcium 3-methyl-2-oxovalerate. The method comprises the following steps of: dripping diethyl oxalate into an alcoholic solution of sodium alkoxide; dripping 2-methyl butyraldehyde, keeping the temperature, stirring, adding an alkali solution, regulating the acid after heat insulation is ended, extracting, and adding a certain amount of water into an extracting solution; adding the alkali solution to regulate the pH, dripping an aqueous solution of calcium chloride for salifying to obtain the coarse 3-methyl-2-oxovalerate product; and refining the coarse 3-methyl-2-oxovalerate product in a mixed solvent of purified water and organic solvent, and obtaining the refined 3-methyl-2-oxovalerate product. The process is mild in reaction conditions, easy to operate, fewer in steps, high in yield and high in quality, the adopted raw materials are cheap and basically do not cause pollution, waste gas and lots of waste residues are avoided, and the method is suitable for industrial production.

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.

The invention discloses an alcohol dehydrogenase mutant and a use thereof. The alcohol dehydrogenase mutant is shown in the formula (1) and / or (2). (1) Phenylalanine at 147th of an amino acid sequenceshown in the formula of SEQ ID NO.1 is replaced by leucine, isoleucine, methionine or cysteine. (2) Alanine at 202th of the amino acid sequence shown in the formula of SEQ ID NO.1 is replaced with leucine, isoleucine or valine. A semi-rational design is used to modify the alcohol dehydrogenase LkADH derived from Lactobacillus kefir so that a plurality of alcohol dehydrogenase mutants are obtained. The alcohol dehydrogenase mutant has the characteristics of high enzyme activity, can efficiently catalyze t-butyl 6-chloro-3, 5-dicarbonylcaproate to prepare t-butyl (S)-6-chloro-5-hydroxy-3-carbonylcaproate and has a great significance for the production of statin drug intermediates.

The present invention designs and synthesizes a fluorescent sensor capable of single and selective recognition of L-arginine, which first uses 4,4´-biphenol and hexamethylenetetramine as substrates in a trifluoroacetic acid solvent The reaction produces 4,4´-biphenol derivatives; and then reacts in absolute ethanol with isoniazid and 4,4´-biphenol derivatives as substrates to obtain the target fluorescent sensor FINH. DMSO‑H in fluorescent sensors 2 O solution, respectively add L-glycine, L-alanine, L-valine, L-leucine, L-isoleucine, L-methionine, L-proline, L- Tryptophan, L-Serine, L-Tyrosine, L-Cysteine, L-Phenylalanine, L-Asparagine, L-Glutamine, L-Threonine, L-Asparagine amino acid, L-glutamic acid, L-lysine, L-arginine and L-histidine, and found that only the addition of L-arginine can enhance the fluorescence of the fluorescent sensor FINH, thus realizing Highly sensitive and single selective recognition of L-arginine.

A method for treating and / or preventing osteoarthritis includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

The present invention discloses a pearl-derived functional peptide and a use thereof. An amino acid sequence of the functional peptide is methionine-isoleucine-isoleucine-leucine-leucine-cysteine-serine-leucine-leucine (MIILLCSLL). The functional peptide has a good function of scavenging free radicals in organisms, an antioxidant function and a melanin cytochrome synthesis inhibitory activity, andthus the functional peptide can be used for preparing radical scavengers, antioxidants and cosmetic raw materials having a whitening function.